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Abstract. N,N-Dimethyl-D-erythro-sphingosine (DMS) is 
known to induce cell apoptosis by specifically inhibiting 
sphingosine kinase 1 (SPHK1) and modulating the activity of 
cellular ceramide levels. The present study investigated the 
effects and the mechanism(s) of action of DMS in human lung 
cancer cells. We found that DMS dose-dependently suppressed 
cell proliferation and induced cell apoptosis in the human lung 
cancer cell line, A549. Mechanistically, treatment with DMS 
suppressed the activation of SPHK1 and nuclear factor-κB 
(NF-κB) p65, but increased intracellular [Ca2+]i in A549 cells. 
This study demonstrates that DMS triggers the apoptosis of 
human lung cancer cells through the modulation of SPHK1, 
NF-κB and calcium signaling. These molecules may represent 
targets for anticancer drug design.
Introduction
N,N-Dimethyl-D-erythro-sphingosine (DMS) (Fig. 1) is 
biologically derived from sphingosine and has been detected in 
several tissues (1). It has been reported that DMS can modulate 
phosphorylation events by inhibiting protein kinase (2) along 
with sphingosine kinase (3). DMS can inhibit the activity of 
sphingosine kinase 1 (SPHK1), resulting in an increase in 
ceramide levels and a decrease in sphingosine-1-phosphate (S1P) 
levels within the cell events involved in cell differentiation and 
apoptosis (4-6).
The nuclear factor-κB (NF-κB) family is involved in 
cellular responses to stimuli such as stress, cytokines, free 
radicals, ultraviolet irradiation, oxidized LDL and bacterial or 
viral antigens. Upon induction, it can transfer to the nucleus 
and stimulate the expression of various target genes, which 
play several crucial functions, including resistance to apoptosis 
and promotion of cell survival. Increased SPHK activity can 
alter the sphingolipid signal and NF-κB p65 expression and can 
eventually lead to the drug resistance of breast cancer cells (7). 
Inhibition of basal SPHK1 activity has been shown to induce 
apoptosis in A549 cells by interfering with constitutive NF-κB 
activity (8).
Calcium is an ubiquitous second messenger that controls 
a broad range of cellular functions. Previous studies have 
reported that DMS increases Ca2+ concentration within cells, 
including T lymphocytes, monocytes, astrocytes, neuronal 
cells (9-12) and HCT116 human colon cancer cells (13).
Lung cancer is a common aggressive malignancy world-
wide with limited treatment options available. Experimental 
research has shown that SPHK1 inhibitor can significantly 
improve the curative effects of chemotherapy drugs on lung 
cancer cells, as well as other types of cancer cells (14-16). 
However, its mechanistic action has yet to be extensively 
investigated. In the present study, the effects of DMS on 
human lung cancer cells were examined. Further, the mecha-
nistic link between DMS and SPHK1 expression, the NF-κB 
pathway and intracellular Ca2+ concentration in A549 cells 
were investigated.
Materials and methods
Reagents. DMS was purchased from Enzo Life Sciences 
(Enzo, New York, NY, USA) and was dissolved in dimethyl 
sulfoxide (DMSO). The final concentrations of DMSO were 
≤0.1% in the drugs. Antibodies to SPHK1, NF-κB p65, poly-
ADP-ribose polymerase (PARP) and GAPDH were purchased 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). 
All other reagents were purchased from Sigma-Aldrich 
(St. Louis, MO, USA).
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Cell culture. The human lung cancer cell line, A549, was main-
tained in RPMI-1640 culture medium (Invitrogen, Carlsbad, 
CA, USA) supplemented with streptomycin (100 µg/ml) and 
penicillin (100 U/ml), glutamine (2 mM) and 10% (v/v) fetal 
bovine serum. The cells were grown at 37˚C in a humidified 
atmosphere containing 5% CO2.
Morphological observations. Cells (5x105/well) were plated in 
6-well plates. After 12 h, the cells were exposed to serial dilu-
tions of DMS (1, 2, 4 and 8 µmol/l) for the times indicated. The 
changes in cell morphology were observed under an inverted 
microscope at 48 h.
Cell proliferation assay. Cells (6x103/well) were transferred in 
5 replicates to 96-well plates in 100 µl medium. All cells were 
incubated at 37˚C in 5% CO2 for 12 h to allow the cells to attach 
to the bottom of the wells. Serial dilutions of DMS (0.5, 1, 2, 4, 
8 µmol/l) were added and the control group was supplemented 
with equal volumes of phosphate-buffered saline (PBS). At the 
culture times of 24, 48 and 72 h, the viability of the cells was 
analyzed after the addition of MTT and DMSO, respectively. 
Absorbance was determined using an enzyme mark instru-
ment at a wavelength of 490 nm.
Colony formation assay. The cells were washed, trypsinized 
and resuspended in culture medium, then counted and plated 
in 60-mm dishes (200 cells/dish) in triplicate and cultured 
in medium with serial dilutions of DMS, grown for 3 weeks, 
fixed with 10% methanol and stained with 2% crystal violet for 
20 min. The dishes were washed and dried, and the colonies 
were counted to obtain a cloning efficiency for each DMS 
concentration.
Analysis of cell apoptosis. The number of apoptotic cells 
was measured by staining the cell nuclei with Hoechst 33342 
dye and the apoptotic cells were identified as those with 
condensed, fragmented nuclei. The cells were stained with 
5 µl Hoechst 33342 (1 g/l) and incubated at 37˚C in the dark 
for 30 min following treatment with DMS at concentrations of 
1 and 2 µmol/l for 24 and 48 h. Cell morphology was observed 
under a fluorescence microscope.
Flow cytometric analysis of apoptosis was performed by 
staining the cells with Annexin V-FITC and propidium iodide 
(PI). Cells (5x105/well) were plated in 6-well plates and incubated 
overnight to attach to the bottom of the wells. Serial dilutions of 
DMS were then added and the control group was supplemented 
with equal volumes of PBS. After 48 h, the control or treated cells 
were resuspended in Annexin V-binding buffer, stained with 
fluorescein-conjugated Annexin V and PI (Annexin V-FITC 
kit; Becton Dickinson, Franklin Lakes, NJ, USA) and incubated 
at room temperature for 15 min. The cells stained only with 
Annexin V-FITC were used as the positive controls to set the 
apoptotic window, and the cells stained only with PI were used 
as the positive controls to set the necrotic window.
DNA fragmentation analysis. Cells were plated in a 6-well 
plate and treated with serial dilutions of DMS. Twenty-four 
and 48 h later, the cells were collected by scraping and centri-
fuged at 600 x g for 10 min. The cells were then washed twice 
with PBS and DNA fragmentation was extracted using the 
Genome extraction kit (Generay Biotechnology, Shanghai, 
China) according to the manufacturer's instructions. The DNA 
samples were subjected to electrophoresis on a 2% agarose gel 
and were then visualized under UV light after staining with 
ethidium bromide.
Caspase-3 activity assay. Cells were plated in 6-well plates 
and treated with serial dilutions of DMS for 24 and 48 h. 
Subsequently, the cells were washed twice with cold PBS and 
lysed in lysis buffer (Beyotime Institute of Biotechnology, 
Shanghai, China) and placed on ice for 15 min. A sample of 
cytosolic protein was formed by centrifugation at 5,000 x g 
for 10 min and protein concentration was determined by the 
Bradford method. Cell extracts (30 µg protein) were incubated 
in reaction buffer containing Ac-DEVD-pNA (2 mM) at 37˚C 
for 2 h. Cleavage of the pNA fluorescence was detected using 
an enzyme mark instrument at an excitation wavelength of 
405 nm. Caspase-3 activity was presented as units of fluores-
cence/(mg of protein x h).
Quantitative RT-PCR (qRT-PCR). Cells were washed with 
cold PBS and then harvested using TRIzol reagent (Invitrogen, 
Carlsbad, CA, USA); total RNA was extracted according to the 
manufacturer's instructions. The extracted RNA was reverse 
transcribed into cDNA. The reverse transcription reaction 
system was 10 µl: 5X reaction buffer 2 µl, M-MuLV reverse 
transcriptase 0.5 µl, primer mix 0.5 µl, RNA 1 µg and DEPC 
added to a final volume of 10 µl. The samples were kept at 37˚C 
for 15 min and were then incubated at 98˚C for 5 min. The 
PCR components were set up as follows: 1 µl cDNA product, 
12.5 µl master mix, 10 pmol/µl forward primer, 10 pmol/µl 
reverse primer and DEPC added to a final volume of 25 µl. 
PCR was performed with 30 cycles of denaturation: 5 min 
at 95˚C, 30 sec at 94˚C, 40 sec at 57˚C, and extension 30 sec 
at 72˚C. The primers were designed using primer 5 software. 
SPHK1 forward, 5'-gtt cca aga cac ctg cct cc-3' and reverse, 
5'-cac gca acc gct gac cat-3'; GAPDH forward, 5'-ggt gtg aac 
cat gag aag tat gac-3' and reverse, 5'-tgg cag tga tgg cat gga 
ctg tg-3'. The amplified DNA fragment was separated on gel 
electrophoresis and analyzed by Applied Biosystems 7300 real-
time PCR software.
Western blot analysis. Cells were washed with cold PBS gently, 
supplemented with 100 µl/well cell lysis buffer (Beyotime 
Institute of Biotechnology) and placed on ice for 15 min. 
A sample of cytosolic protein was formed by centrifuga-
tion at 14,000 x g for 10 min and protein concentration were 
determined by the BCA method. The proteins (40 µg) were 
separated by 12% SDS-PAGE and then transferred onto PVDF 
membranes (Millipore, Bedford, MA, USA). The blots were 
blocked with 5% non-fat milk and then probed with primary 
antibodies (1:1,000 dilution) against the SPHK1 and GAPDH 
Figure 1. Chemical structure of N,N-dimethyl-D-erythro-sphingosine (DMS).
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protein at 4˚C overnight. After washing, the membranes were 
incubated with secondary antibody (1:10,000 dilution) at room 
temperature. Antibodies were diluted in TBS containing 0.05% 
(v/v) Tween-20 and 5% BSA. Proteins were analyzed using the 
near infrared laser imaging system.
Measurement of [Ca2+]i concentration. The intracellular 
[Ca2+]i concentration was measured using the fluorescent dye, 
Fluo-4/AM (Dojindo Laboratories, Kumamoto, Japan). The 
cells were treated with serial dilutions of DMS for 24 and 
48 h, then resuspended in PBS containing 1% bovine serum 
and incubated for 30 min with 5 µM Fluo-4/AM in the dark. 
After washing with PBS, the Fluo-4/AM-labeled cells were 
observed under an inverted fluorescence microscope.
Results
Morphological alteration of A549 cells following treatment 
with DMS. To explore the effects of DMS on the A549 cells, 
the cells were exposed to serial dilutions of DMS for 24 h. 
Cell morphology was observed under an inverted microscope. 
DMS dose-dependently altered the morphology of the A549 
cells. At the concentration of 4 µmol/l, cell shrinkage and 
rounding was observed. Vacuoles were also observed in the 
cytoplasm (Fig. 2). The induction of apoptosis was further 
confirmed by Hoechst 33342 staining. Under a fluorescence 
microscope, with increasing concentrations of DMS, cell 
shrinkage, nuclear fragmentation, nuclear dissolution and 
apoptotic bodies were observed (Fig. 3).
Figure 2. Changes in cell morphology were observed microscopically. (A) The number of viable cells of A549 markedly decreased after treatment with N,N-
dimethyl-D-erythro-sphingosine (DMS) at the concentration of 4 µmol/l for 48 h. Original magnification, x100. (B) Cell shrinkage and rounding was observed 
and vacuoles were also observed seen in the cytoplasm following treatment with DMS at concentrations of 0 and 4 µmol/l for 24 h. Original magnification, x200.
Figure 3. Staining with Hoechst 33342 after treatment with N,N-dimethyl-D-erythro-sphingosine (DMS) at concentrations of 0, 1 and 2 µmol/l for 24 h. Cells 
showed body shrinkage, nuclear fragmentation, nuclear dissolution and apoptotic bodies. Original magnification, x320.
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Cytotoxicity of DMS in A549 cells. The A549 cells were 
treated with serial dilutions of DMS for 24, 48 and 72 h. MTT 
assays were used to measure the cytotoxicity of DMS in the 
A549 cells. Treatment with DMS decreased the viability of 
the A549 cells in a dose- and time-dependent manner (Fig. 4). 
When DMS concentration reached 4 µmol/l, the cell survival 
rates were significantly decreased by 37.74±3.1, 36.25±2.82 
and 46.5±5.11% (mean ± SD, n=6, P<0.01) at 24, 48 and 72 h, 
respectively (Fig. 4). The IC50 values for 24, 48 and 72 h were 
4.864, 4.788 and 4.456 µmol/l respectively, calculated using 
SPSS 16.0 software.
Inhibition of cell colony formation by DMS. To determine 
the effects of DMS on the ability of single cell proliferation, 
colony formation assay was performed. Colony formation 
efficiency was calculated with the number of visible colonies 
divided by the number of plated cells. Treatment with DMS 
suppressed colony formation in a dose-dependent manner. 
Once the concentration was >2 µmol/l, the growth of the A549 
cells was almost completely inhibited, with a colony formation 
rate of <1% (Fig. 5).
DMS induces cell apoptosis by activating the apoptotic 
signaling pathway. The A549 cells were treated with 
various concentrations of DMS for 24 and 48 h, stained with 
Annexin V-FITC and PI, and analyzed by flow cytometry 
(Fig. 6A). FITC single-positive cells represent early apop-
totic cells, FITC/PI double-positive cells represent apoptotic 
cells and PI single-positive cells represent dead cells. The 
percentages of apoptotic cells increased with the increasing 
DMS concentrations and with the prolonged exposure time. 
However, following treatment with 4 µmol/l DMS for 48 h, 
the percentage of dead cells reached 40.5% and the number of 
apoptotic cells in turn decreased. These results were further 
confirmed by DNA fragmentation assay. Treatment of the cells 
with DMS (4 µmol/l for 24 h, 2 and 4 µmol/l for 48 h) resulted 
in a classical laddering pattern, whereas no DNA laddering 
was observed in the controls (Fig. 6B).
In order to investigate the signaling involved in DMS stimu-
lation, caspase-3 activation in response to DMS was measured 
and the expression of PARP was analyzed by western blot 
analysis. The results revealed an increase in caspase-3 activity 
following treatment with DMS (1 µmol/l). It reached a plateau 
from 2 to 4 µmol/l. In addition, as a substrate of caspase-3, 
PARP was cleaved in a time- and concentration-dependent 
manner (Fig. 7).
DMS suppresses gene expression of SPHK1. To investigate 
the effects of DMS on SPHK1 gene expression, we analyzed 
the mRNA levels of SPHK1 in A549 cells by RT-PCR. The 
results revealed that the mRNA levels of SPHK1 were mark-
edly downregulated following treatment with DMS at 2 and 
4 µmol/l for 48 h. In addition, qRT-PCR revealed that the 
mRNA levels of SPHK1 decreased by 35.28 and 34.64% when 
the cells were treated with 2 and 4 µmol/l DMS, respectively 
for 48 h (Fig. 8), indicating that DMS inhibits the expression of 
SPHK1 at the transcriptional level.
Figure 4. Cytotoxic activity of N,N-dimethyl-D-erythro-sphingosine (DMS) 
on A549 cells. Cells were treated with DMS at different concentrations for 
24, 48 and 72 h. Cell viability was assayed by the MTT test. Shown is a 
representative result from at least 3 independent experiments.
Figure 5. N,N-Dimethyl-D-erythro-sphingosine (DMS) inhibits A549 cell 
clonogenicity. Data are the means ± SD of 3 independent experiments.
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Figure 6. Apoptosis detection assay. (A) Cell apoptosis was observed by flow 
cytometry analysis after treatment with different concentrations of N,N-
dimethyl-D-erythro-sphingosine (DMS) (0, 1, 2 and 4 µmol/l) for 24 and 
48 h, respectively. (B) DNA fragmentation analysis after treatment with DMS 
for 24 and 48 h. M, DNA size markers; 1, untreated cells; 2, cells treated with 
4 µmol/l DMS for 24 h; 3 and 4, cells treated with 2 and 4 µmol/l DMS for 
48 h, respectively. Both panels are representative of 3 experiments. 
Figure 7. N,N-Dimethyl-D-erythro-sphingosine (DMS) activates the apoptosis signaling pathway. (A) Caspase-3 activity was measured in total lysates obtained from 
treated or untreated cells at 24 and 48 h after treatment. Data are means ± SD of three independent experiments. (B) A549 cells were treated with different concentra-
tions of DMS for 24 and 48 h. Marked increase of PARP, apoptosis-related protein, was observed using western blot analysis. Data are from 3 independent experiments.
Table I. Summary of changes in SPHK1 expression in cancer tissues.
   Associated with
Tumor type SPHK1 expression (Refs.) Prognostic association (Refs.) drug resistance (Refs.)
Breast Increase (23,24) Yes (23) Yes (25)
Prostate Increase (26)  Yes (27)
Ovary Increase (28)
Glioblastoma  Yes (29)
Liver Increase (30)
Gastrointestinal Increase (31)
AML Increase (32)  Yes (16)
Lung Increase (33)  Yes (34)
Melanoma  Yes (35) Yes (36)
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DMS inhibits SPHK1 and NF-κB activation. Western blot 
analysis indicated that the expression of SPHK1 and the 
NF-κB p65 subunit decreased, with the increasing DMS 
concentrations and the prolonged treatment time. Therefore, 
the inhibition of NF-κB activity and SPHK1 expression may be 
responsible for the induction of cell apoptosis by DMS (Fig. 9).
DMS increases intracellular Ca2+ concentration. The A549 
cells were treated with various concentrations of DMS for 
24 and 48 h and then incubated with Fluo-4-AM for 30 min. 
Fluo-4-AM can conjugate with [Ca2+]i and thus generate 
strong fluorescence in 405 nm after excitation light; therefore, 
intracellular [Ca2+]i levels can be indirectly visualized under 
an inverted fluorescence microscope. We observed that DMS 
increased intracellular [Ca2+]i concentrations in the A549 cells 
(Fig. 10).
Discussion
Tumor progression depends mainly on the degree of cell prolif-
eration and cell loss, and apoptosis is the main source of cell 
loss. SPHK1 is highly expressed in several types of tumor cells 
(approximately 2-3-fold higher) and its ability to prevent apop-
tosis has been extensively demonstrated (Table I) (17). There 
is evidence that the overexpression of SPHK1 contributes to 
cellular resistance to chemotherapy drugs (7). As an inhibitor 
of SPHK1, the anticancer properties of DMS have been widely 
investigated in preclinical models. The inhibition of tumor cell 
growth and migration by DMS has been reported (18-20) with 
a Ki value of 5 µmol/l (21,22). Moreover, the dose of DMS and 
tumor growth inhibition positively correlated in animal model 
of tumor-burdened nude mice.
Figure 8. mRNA expression of specifically inhibiting sphingosine kinase 1 (SPHK1) in A549 cells. A549 cells were treated with various concentrations of 
N,N-dimethyl-D-erythro-sphingosine (DMS) for 24 and 48 h. SPHK1 mRNA expression was determined by RT-PCR and qRT-PCR. Data are the means ± SD 
of 3 independent experiments.
Figure 9. N,N-Dimethyl-D-erythro-sphingosine (DMS) specifically inhibits 
sphingosine kinase 1 (SPHK1) and the activation of the nuclear factor-κB 
(NF-κB) signaling pathway. Western blot assay was used to investigate the 
protein expressions of SPHK1 and NF-κB subunit p65 in A549 cells, treated 
with different concentrations of DMS for 24 and 48 h. Data are from 3 inde-
pendent experiments.
Figure 10. N,N-Dimethyl-D-erythro-sphingosine (DMS) increases intracel-
lular Ca2+ concentration. (Control) Untreated cells; (A and B) cells treated 
with 2 and 4 µmol/l DMS for 24 h, respectively; (C-E) cells treated with 1, 2 
and 4 µmol/l DMS for 48 h, respectively. Original magnification, x200. Data 
are representative of 3 independent experiments.
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The NF-κB signaling pathway in tumor biology has 
attracted considerable attention. It has been reported that cells 
expressing high levels of NF-κB are resistant to chemotherapy 
and radiotherapy (37). The inhibition of NF-κB activation 
sensitizes tumor cells to chemotherapy (38,39) and eventu-
ally lead to apoptosis. Consistently, in our study, we observed 
that triggering apoptosis in the A549 cells was associated 
with the inhibition of NF-κB activation. In fact, NF-κB is a 
calcium-dependent transcription factor (40). The disturbance of 
intracellular calcium triggers the elevation of reactive oxygen 
species in the mitochondria and leads to the translocation of 
NF-κB into the nucleus (41). A previous study reported that 
DMS increases the [Ca2+]i concentration in U937 and HCT116 
cells (13). In the present study, we confirmed that DMS 
increased intracellular [Ca2+]i levels in A549 cells.
Billich et al (8) reported that the suppression of SPHK1 
activation by DMS diminished NF-κB activity due to the 
reduced nuclear translocation of RelA (p65), resulting in 
spontaneous apoptosis in A549 cells. This is consistent with 
our experimental results. However, in our study, NF-κB 
activity was not increased, despite the increase in intracellular 
[Ca2+]i levels in A549 cells after treatment of DMS. These 
results suggest that other mechanisms may exist between the 
SPHK1 pathway and intracellular calcium signaling in terms 
of regulating NF-κB activity. When the SPHK1 pathway plays 
a major role, NF-κB activity may be diminished. By contrast, 
when intracellular calcium signaling plays a dominant role, 
NF-κB activity may be increased. However, the exact role 
of the SPHK1 pathway, calcium channels and the NF-κB 
signaling network in regulating the growth of cancer cells 
remains to be further elucidated.
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